RxDoctor Payments Data

Allison Manning

Family · Vestal, NYNPI 1578128435

Payments from drug & device makers

$3,880in general payments, 2019–2025

Across 196 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$910
  • GSK$757
  • Pfizer$341
  • Exact Sciences$291
  • AstraZeneca$244
  • plus $107 from 5 others

What the payments were for

  • Food & beverage$3,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie62$1,229
Novo Nordisk42$910
GSK51$757
Pfizer19$341
Exact Sciences9$291
AstraZeneca8$244
Lilly USA, LLC1$23
Merck1$23
Johnson & Johnson1$22
Amgen1$20
Vertex1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,880 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$34,654
Medicare patients
143
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate26$36,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$28,152
JardianceEmpagliflozin21$24,280
XareltoRivaroxaban16$18,439
OzempicSemaglutide11$13,892
MyrbetriqMirabegron15$6,053
OxycontinOxycodone Hcl12$3,492
Levothyroxine Sodium106$1,646
SynthroidLevothyroxine Sodium23$1,324
Atorvastatin Calcium128$1,237
Albuterol Sulfate HfaAlbuterol Sulfate37$1,202
Lisinopril134$920
Misoprostol13$888
Metformin Hcl ErMetformin Hcl55$872
Duloxetine Hcl29$862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$23$36,32926 claims
GSKTrelegy Ellipta$757$28,15235 claims
Johnson & JohnsonXarelto$22$18,43916 claims
Novo NordiskOzempic$910$13,89211 claims
AbbVieSynthroid$1,229$1,32423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Vestal

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →